EU launch: sentinel lymph node identification (Japan)

Our company is specialized in R&D of medical devices and equipment for diagnosis of cancer metastasis, anti-Tenascin antibody therapy, medical supplies, medical-use cells, pharmaceuticals and diagnostic agents, as well as new technologies for diagnosis and treatment in regenerative medicine.

We have developed a handheld magnetic probe designed to detect magnetic fluids injected during sentinel lymph node biopsy (SLNB).

Unlike conventional radioisotope methods, sentinel lymph node biopsy with magnetic tracers and probes enables even small- to medium-sized medical institutions that may not have nuclear medicine facilities to accurately diagnose cancer metastasis. The diagnosis of cancer metastasis can be performed during surgery and is radiation-free and minimally invasive. This greatly increases cancer patients’ overall quality of life.

The magnetic probe is CE Marking certified.

Our company wants to make its market debut in the EU and is seeking partners (ditributors).

Opportunity reference

# 899

Expiration

2021-10-14

Value (€)

500k-1M

Country

Europe

Industry

Health and Pharma

View other opportunities

Offering: snacks, dried fruits, seeds, spices, sugar, food additives, cacao and more
Looking for acquisition or JV in the electronic hospitality and leisure service market
Polish manufacturer of coffee looking for foreign distributors

Copyright © Globartis 2021 - Version 3.2.1 - Last update 04-sep-21 - Powered with by  Giplo